Sign Up for Free Access to the
Latest Clinical Updates in Your Specialty!

Receive conference highlights, journal articles, and online medical education activities straight to your inbox.

Never Miss an Update

3D Rendered Medical Illustration of Male Anatomy - Colon Cancer; Ascending Colon.

Advances in Targeting KRAS G12C in Gastrointestinal Malignancies: Focus on KRAS G12C Inhibitors

Celine Hoyek, Angelo Pirozzi, Jeremy Jones

Rat sarcoma virus (RAS) proteins are a family of prototypical oncogenes frequently mutated in human cancers. Mutations in the RAS gene account for 19% of all pathogenic alterations and are the subject of extensive research in molecular and clinical oncology.1 The RAS family consists of three major isoforms, namely the Harvey rat sarcoma virus (HRAS), the neuroblastoma RAS […]

touchREVIEWS in Oncology & Haematology. 2024;20(2):1–7:Online ahead of journal publication

Gynaecological Cancers

2 mins

Keiichi Fujiwara, ESMO 2022: Clinical trial highlights in gynaecological cancer

Published Online: Sep 12th 2022

Dr Keiichi Fujiwara joins touchONCOLOGY to discuss his thoughts on the latest clinical trial highlights at European Society for Medical Oncology (ESMO) 2022 in gynaecological cancers, specifically the GOTIC-002 LUFT study.

Watch Dr Keiichi Fujiwara’s interview at ESMO 2022, on the Phase 3 GOTIC-002 LUFT study results – chemotherapy with tegafur-uracil for locally advanced cervical cancer

Questions:

What are the hot topics and clinical trial highlights in gynaecological cancer from ESMO?

Disclosures: Keiichi Fujiwara receives grant/research support from Taiho; is on the advisory board for Daiichi Sankyo, Seagen, and Genmab; and receives honoraria/honorarium from Kiowa KIRIN.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Katey Gabrysch.

Filmed in coverage of ESMO 2022

Access more gynaecological oncology here

Niraparib as first-line maintenance treatment in ovarian cancer

Antonio González Martín

The phase III PRIMA/ENGOT-OV26/GOG-3012 trial evaluated the efficacy of niraparib as a first-line maintenance treatment for patients with advanced ovarian cancer who responded to platinum-based chemotherapy. In this final analysis, no significant difference in overall survival was observed between niraparib and placebo in the overall or homologous recombination-deficient (HRd) populations. However, long-term progression-free survival and […]

Related Videos in Gynaecological Cancers

Developed by Touch

Addition of nivolumab to rucaparib did not improve clinical outcomes in newly diagnosed, advanced, high-grade ovarian cancer

Bradley J Monk

The ATHENA trial evaluated the effectiveness of rucaparib (RUCA) monotherapy (MONO) and rucaparib combined with nivolumab (NIVO) (COMBO) in patients with advanced high-grade ovarian cancer (AHGOC). In the MONO arm, rucaparib showed sustained progression-free survival (PFS) of 20.2 months after first-line ...

ESGO 24: Advances in cervical, endometrial and ovarian cancer

Jalid Sehouli

The annual European Society of Gynaecological Oncology (ESGO) Congress, held from 7–10 March 2024, in Barcelona, Spain, celebrated its 25th anniversary this year. This year’s congress brought together over 2,500 participants from all over the world, and featured groundbreaking research, clinical advancements and professional development opportunities.

Key insights in gynecological malignancies: BrUOG 354, AGO-OVAR 2.29/ENGOT-ov34, KEYVIBE-005, CARACO

Domenica Lorusso

To further understand the key developments and research presented in the field of gynaecological oncology at ASCO 2024, we spoke with Dr. Domenica Lorusso, Professor of Obstetrics and Gynaecology at Humanitas University of Milan, Italy. In this interview, Dr. Lorusso discusses the findings from the BrUOG 354 (NCT03355976), AGO-OVAR 2.29/ENGOT-ov34 (NCT03353831), KEYVIBE-005 (NCT05007106), and CARACO (NCT01218490) trials, offering her valuable insights into the potential impact these results could have on clinical practice.

Developed by Touch

Highlights in gynaecological oncology: Domenica Lorusso, ESMO 2023

To further understand the key developments and research presented in the field of gynaecological oncology at ESMO 2023, we spoke with Dr Domenica Lorusso, Professor of Obstetrics and Gynaecology at the Fondazione Policlinico Universitario Agostino Gemelli - UCSC Italy. In our ...

Developed by Touch

Navigating HRT and cancer risk: PrEvCan | Celia Diez de los Rios

This July, the PrEvCan campaign is dedicated to raising awareness about women's cancer risk in connection with breastfeeding and hormone replacement therapy (HRT). Initiated by the European Oncology Nursing Society (EONS), and with ESMO as a key campaign partner, the ...

Developed by Touch

Cancer prevention and the power of breastfeeding: PrEvCan | Celia Diez de los Rios

The relationship between breastfeeding and a reduction in cancer risk is the focus of the PrEvCan Campaign, this July. Initiated by the European Oncology Nursing Society (EONS), and with ESMO as a key campaign partner, the PrEvCan – Cancer Prevention Across ...

Developed by Touch

Paul DiSilvestro, ESMO 2022: SOLO1/GOG-3004 trial - Olaparib for the treatment of advanced ovarian cancer - Overall survival findings at 7 years

The Phase III SOLO1/GOG-3004 trial (NCT01844986), investigated maintenance olaparib, which provided sustained benefit beyond the end of treatment in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation. Prof. Paul DiSilvestro (Brown University, Providence, RI, USA) joins ...

Developed by Touch

Keiichi Fujiwara, ESMO 2022: Phase 3 GOTIC-002 LUFT study results - Chemotherapy with tegafur-uracil for locally advanced cervical cancer

Maintenance chemotherapy with oral tegafur-uracil (UFT) after surgery has been shown to prolong survival in lung, breast, gastric and colon cancer. Dr Keiichi Fujiwara (Saitama Medical University International Medical Centre, Saitama, Japan) joins touchONCOLOGY to discuss the phase 3 GOTIC-002 LUFT ...

Domenica Lorusso, ASCO 2022: Trabectedin for the treatment of recurrent ovarian, primary peritoneal, or fallopian tube cancers - Phase 3 MITO23 trial results

The phase 3 MITO23 trial investigated trabectedin (ET-743) single agent versus clinician’s choice chemotherapy in recurrent ovarian, primary peritoneal, or fallopian tube cancers of BRCA-mutated or BRCAness phenotype patients Dr Domenica Lorusso (Fondazione IRCCS National Cancer institute of Milan, Milan, ...

Developed by Touch

Ruth Perets, AACR 2022: Vibostolimab / Pembrolizumab Coformulation for the Treatment of Ovarian Cancer Naive to PD-1/PD-L1 Inhibitors

We were delighted to speak with Dr. Ruth Perets (Rambam Health Care Campus, Haifa, Israel) about the efficacy and safety findings of the phase 1 study comparing vibostolimab (vibo) plus pembrolizumab (pembro) given sequentially to the coformulation of vibo/pembro in ...

Domenica Lorusso, ESMO 2021: Relacorilant in Combination with Nab-paclitaxel for Patients with Recurrent Platinum-resistant Ovarian Cancer

touchONCOLOGY joins Dr Domenica Lorusso (Rome, Italy), to discuss the improvements in progression-free survival in patients with recurrent platinum-resistant ovarian cancer using relacorilant in combination with nab-paclitaxel. (NCT03776812) Question Please summarise the randomized, open-label, phase II study presented at ESMO 2021 ...

Julius Strauss, ESMO 2021: Long-term Follow-up of Patients with HPV–associated Malignancies Treated with Bintrafusp Alfa

touchONCOLOGY joins Dr Julius Strauss (National Cancer Institute, National Institutes of Health, Bethesda, MD, USA), to discuss the long-term follow-up of patients with human papillomavirus–associated malignancies treated with bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1. Questions 1. ...

Latest articles videos and clinical updates - straight to your inbox

Log into your Touch Account

Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.

Error:

Forgot Password?

Or log in with

By proceeding, you agree to our terms & conditions.

For information about how we
use your data, see our privacy policy.

Register now for FREE Access

Register for free to hear about the latest expert-led education, peer-reviewed articles, conference highlights, and innovative CME activities.

Already have an Account?

Sign up with an Email

Or use a Social Account.

Error:

By clicking sign up you agree to the website
terms & conditions and privacy policy.

This Functionality is for
Members Only

Explore the latest in medical education and stay current in your field. Create a free account to track your learning.

Sign Up for Free Access to the
Latest Clinical Updates in Your Specialty!

Conference Coverage

Learning Activities

Journals

Advances in Targeting KRAS G12C in Gastrointestinal Malignancies: Focus on KRAS G12C Inhibitors

Conference Coverage

Learning Activities

Journals

Advances in Targeting KRAS G12C in Gastrointestinal Malignancies: Focus on KRAS G12C Inhibitors

Keiichi Fujiwara, ESMO 2022: Clinical trial highlights in gynaecological cancer

Niraparib as first-line maintenance treatment in ovarian cancer

Addition of nivolumab to rucaparib did not improve clinical outcomes in newly diagnosed, advanced, high-grade ovarian cancer

ESGO 24: Advances in cervical, endometrial and ovarian cancer

Key insights in gynecological malignancies: BrUOG 354, AGO-OVAR 2.29/ENGOT-ov34, KEYVIBE-005, CARACO

Highlights in gynaecological oncology: Domenica Lorusso, ESMO 2023

Navigating HRT and cancer risk: PrEvCan | Celia Diez de los Rios

Cancer prevention and the power of breastfeeding: PrEvCan | Celia Diez de los Rios

Paul DiSilvestro, ESMO 2022: SOLO1/GOG-3004 trial - Olaparib for the treatment of advanced ovarian cancer - Overall survival findings at 7 years

Keiichi Fujiwara, ESMO 2022: Phase 3 GOTIC-002 LUFT study results - Chemotherapy with tegafur-uracil for locally advanced cervical cancer

Domenica Lorusso, ASCO 2022: Trabectedin for the treatment of recurrent ovarian, primary peritoneal, or fallopian tube cancers - Phase 3 MITO23 trial results

Ruth Perets, AACR 2022: Vibostolimab / Pembrolizumab Coformulation for the Treatment of Ovarian Cancer Naive to PD-1/PD-L1 Inhibitors

Domenica Lorusso, ESMO 2021: Relacorilant in Combination with Nab-paclitaxel for Patients with Recurrent Platinum-resistant Ovarian Cancer

Julius Strauss, ESMO 2021: Long-term Follow-up of Patients with HPV–associated Malignancies Treated with Bintrafusp Alfa

Latest articles videos and clinical updates - straight to your inbox

Connect With Us

Useful Links

In Partnership With

Specialities

Sign Up for Free Access to the Latest Clinical Updates in Your Specialty!

Conference Coverage

Learning Activities

Journals

Trending Topic

Connect With Us:

Keiichi Fujiwara, ESMO 2022: Clinical trial highlights in gynaecological cancer

Latest articles videos and clinical updates - straight to your inbox

Log into your Touch Account

Register now for FREE Access

Sign up with an Email

This Functionality is forMembers Only

Sign Up for Free Access to the
Latest Clinical Updates in Your Specialty!

This Functionality is for
Members Only